Amiodarone (cordarone) is a type of medication, which is known as class III antiarrhythmics. It is used to treat and prevent recurrent hemodynamically, irregular heartbeats, ventricular arrhythmias such as ventricular fibrillation, ventricular tachycardia, and wide complex tachycardia, supraventricular tachycardia, atrial fibrillation, and paroxysmal. It relaxes the overactive heartbeat by slowing down the nerve activity. Amiodarone can be used for both life-threatening situation as well as a long-term suppression of arrhythmias, be it supraventricular or ventricular.
COVID-19 Impact analysis
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the amiodarone market.
Top Impacting Factors
- Increase in the geriatric population led to high risk of sudden deaths due to life-threatening ventricular arrhythmias, thus boosting the growth of the amiodarone hydrochloride market.
- Rise in the sedentary lifestyle of people resulted in frequent incidences of heart-related problems and other chronic disorders, which are some of the factors that boost the amiodarone hydrochloride market growth for amiodarone.
- However, side effects such as pulmonary fibrosis in the lungs and might hinder the amiodarone hydrochloride market growth
Market Trends
New product launches to flourish the market
In 2018, Mayne Pharma Group Limited, an Australian pharma company, announced the launch of amiodarone 200mg tablets, a generic alternative to the Cordarone® tablets in the U.S.
In 2021, Piramal Pharma Limited, a pharmaceutical company, took over Hemmo Pharmaceuticals Pvt Ltd., which is a leading Indian manufacturer of Peptide APIs, to enhance product portfolio.
Key Benefits of the Report
- This study presents the analytical depiction of the amiodarone hydrochloride industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the amiodarone hydrochloride market share.
- The current market is quantitatively analyzed to highlight the amiodarone hydrochloride market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the amiodarone hydrochloride market.
- The report provides a detailed amiodarone hydrochloride market analysis depending on competitive intensity and how the competition will take shape in coming years
Questions Answered in the Amiodarone Report
- Who are the leading players active in the amiodarone hydrochloride market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "amiodarone"?
- What is "amiodarone" market prediction in the future?
Amiodarone Hydrochloride Market Report Highlights
| Aspects | Details |
 By Drug Type |
|
 By Purity Level |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Zhejiang Sanmen Hengka,, United Pharma Industri,, PMC Isochem,, Arevipharma,, Cambrex, Ltd,, Piramal Pharma Limited, Olon, Glenmark Pharma,, Shanghai Pharmaceutical Group Co., Sanofi, CTX Lifesciences,, Globe Quimica Ltda,, Unichem Laboratories Limited, |
Loading Table Of Content...
